70 related articles for article (PubMed ID: 28635712)
1. [A prospective, open, non-randomized study on the safety and efficacy of natalizumab (tisabri) in the Russian population of patients with relapsing-remitting multiple sclerosis].
Boyko AN; Evdoshenko EP; Vorob'eva OV; You X; Pukaite V
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(8. Vyp. 2):25-35. PubMed ID: 28635712
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of early natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Campbell JD; McQueen RB; Miravalle A; Corboy JR; Vollmer TL; Nair K
Am J Manag Care; 2013 Apr; 19(4):278-85. PubMed ID: 23725360
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.
Saida T; Kira JI; Kishida S; Yamamura T; Ohtsuka N; Ling Y; Torii S; Lucas N; Kuesters G; Steiner D; Tibung JT;
Neurol Ther; 2017 Jun; 6(1):39-55. PubMed ID: 27921221
[TBL] [Abstract][Full Text] [Related]
5. Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis.
Prosperini L; Giannì C; Barletta V; Mancinelli C; Fubelli F; Borriello G; Pozzilli C
J Neurol Sci; 2012 Dec; 323(1-2):104-12. PubMed ID: 23006974
[TBL] [Abstract][Full Text] [Related]
6. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
7. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
Saida T; Kira JI; Kishida S; Yamamura T; Sudo Y; Ogiwara K; Tibung JT; Lucas N; Subramanyam M;
Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
[TBL] [Abstract][Full Text] [Related]
9. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
[TBL] [Abstract][Full Text] [Related]
11. Long-term effectiveness and safety of natalizumab in a Portuguese population.
Correia I; Batista S; Galego O; Marques IB; Jesus-Ribeiro J; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
Int Immunopharmacol; 2017 May; 46():105-111. PubMed ID: 28282574
[TBL] [Abstract][Full Text] [Related]
12. A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis.
Trojano M; Ramió-Torrentà L; Grimaldi LM; Lubetzki C; Schippling S; Evans KC; Ren Z; Muralidharan KK; Licata S; Gafson AR
Mult Scler; 2021 Dec; 27(14):2240-2253. PubMed ID: 33821693
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
14. Patient and treatment characteristics and safety outcomes of patients with relapsing-remitting multiple sclerosis treated with natalizumab in Greece: Results from the multicenter, 5-year prospective observational study 'TOPICS greece'.
Karanasios P; Karachalios G; Gourgioti R; Alexopoulou A; Mastorodemos V;
Mult Scler J Exp Transl Clin; 2021; 7(3):20552173211035803. PubMed ID: 34377528
[TBL] [Abstract][Full Text] [Related]
15. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
16. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
[TBL] [Abstract][Full Text] [Related]
17. [Pharmacoeconomic analysis of the efficacy of natalizumab in relapsing-remitting multiple sclerosis].
Sabanov AV; Luneva AV; Matveev NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2014; 114(5):65-9. PubMed ID: 24988963
[TBL] [Abstract][Full Text] [Related]
18. Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.
Pietropaolo V; Bellizzi A; Anzivino E; Iannetta M; Zingaropoli MA; Rodio DM; Morreale M; Pontecorvo S; Francia A; Vullo V; Palamara AT; Ciardi MR
J Neurovirol; 2015 Dec; 21(6):653-65. PubMed ID: 25930159
[TBL] [Abstract][Full Text] [Related]
19. Natalizumab for relapsing-remitting multiple sclerosis.
Horga A; Tintoré M
Neurologia; 2011; 26(6):357-68. PubMed ID: 21193250
[TBL] [Abstract][Full Text] [Related]
20. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
Bartt RE
Curr Opin Neurol; 2006 Aug; 19(4):341-9. PubMed ID: 16914971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
